Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹84 Cr
P/E Ratio
13.43
P/B Ratio
1.18
Industry P/E
37.87
Debt to Equity
0.28
ROE
-7.28 %
ROCE
-2.36 %
Div. Yield
0 %
Book Value
120.63
EPS
13.59
CFO
₹31.58 Cr
EBITDA
₹54.31 Cr
Net Profit
₹19.80 Cr
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Makers Lab
| -21.06 | 10.27 | -16.76 | -0.70 | -6.32 | 28.03 | 8.60 |
|
BSE Healthcare
| -6.54 | 1.91 | 1.42 | 18.70 | 20.14 | 22.31 | 10.08 |
|
BSE Small Cap
| -13.49 | 1.63 | -3.38 | 0.28 | 18.33 | 33.99 | 15.77 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Makers Lab
| 25.18 | 14.40 | -35.40 | -34.42 | 677.85 | -42.05 | -36.73 |
|
BSE Small Cap
| 29.04 | 47.52 | -1.80 | 62.77 | 32.11 | -6.85 | -23.41 |
|
BSE Healthcare
| 43.09 | 36.97 | -12.10 | 20.87 | 61.45 | -3.55 | -5.89 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | P/E Ratio | ROE |
|---|---|---|---|---|
| 421.00 | 6,841.28 | 24.93 | 12.5 | |
| 5,082.00 | 8,400.95 | 35.51 | 43.77 | |
| 647.05 | 6,319.25 | 71.58 | 4.01 | |
| 649.90 | 6,082.74 | 22.57 | 12.68 |
No Review & Analysis are available.
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. The company offers products in general health therapeutic segments, including acid regulatory, anthelmintic, anti-allergic,... anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeal, anti-emetics and anti-nauseants, anti-fungal, anti?inflammatory, analgesic, anti-spasmodic, anti-malarial, anti-thyroid, cough and cold control, digestives, neurotonic, nutritional supplements, topical anti-biotic/anti-microbial, and other specialties. It also provides diabetic and hypertensive drugs. The company's principal formulation brands comprise Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin. It serves approximately 1,500 stockiests'; 1,00,000 doctors; and 2,00,000 retailers through a distribution network of 20 consignment agents and 15 super stockiests'. The company was incorporated in 1984 and is based in Mumbai, India. Read more
Incorporated
1984
Chairman
R K P Verma
Managing Director
--
Group
Ipca Laboratories
Headquarters
Mumbai, Maharashtra
Website
Looking for more details about Makers Laboratories Ltd.’s IPO? Explore our IPO Details page.
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The total asset value of Makers Laboratories Ltd stood at ₹ 150 Cr as on 31-Dec-24
The share price of Makers Laboratories Ltd is ₹142.25 (BSE) as of 30-Apr-2025 IST. Makers Laboratories Ltd has given a return of -6.32% in the last 3 years.
Makers Laboratories Ltd has a market capitalisation of ₹ 84 Cr as on 30-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Makers Laboratories Ltd is 1.18 times as on 30-Apr-2025, a 77% discount to its peers’ median range of 5.06 times.
The P/E ratio of Makers Laboratories Ltd is 13.43 times as on 30-Apr-2025, a 65% discount to its peers’ median range of 37.87 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Makers Laboratories Ltd and enter the required number of quantities and click on buy to purchase the shares of Makers Laboratories Ltd.
Makers Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations in India. The company offers products in general health therapeutic segments, including acid regulatory, anthelmintic, anti-allergic, anti-asthmatic, anti-biotic, anti-diabetics, anti-diarrhoeal, anti-emetics and anti-nauseants, anti-fungal, anti?inflammatory, analgesic, anti-spasmodic, anti-malarial, anti-thyroid, cough and cold control, digestives, neurotonic, nutritional supplements, topical anti-biotic/anti-microbial, and other specialties. It also provides diabetic and hypertensive drugs. The company's principal formulation brands comprise Duramol, Artemak-AB, Loroquin, Nimuwin, Coffwin, and Exylin. It serves approximately 1,500 stockiests'; 1,00,000 doctors; and 2,00,000 retailers through a distribution network of 20 consignment agents and 15 super stockiests'. The company was incorporated in 1984 and is based in Mumbai, India.
The prominent promoters of Makers Laboratories Ltd. are
| Name of promoters | Holding percentage |
|---|---|
|
Kaygee Investments Private Limited |
17.38%
|
|
Paschim Chemicals Pvt Ltd |
16.38%
|
|
Kaygee Laboratories Private Limited |
14.35%
|
|
Mexin Medicaments Private Limited |
3.12%
|
The chairman of the company is R K P Verma, and the managing director is .
There is no promoter pledging in Makers Laboratories Ltd.
Some of the close peers are:
| Company | Market Cap(₹ Cr) |
|---|---|
|
8,423
|
|
|
6,920
|
|
|
6,675
|
|
|
6,029
|
| Makers Laboratories Ltd. | Ratios |
|---|---|
|
Return on equity(%)
|
11.97
|
|
Operating margin(%)
|
0.99
|
|
Net Margin(%)
|
6.6
|
|
Dividend yield(%)
|
0
|
Yes, TTM profit after tax of Makers Laboratories Ltd was ₹6 Cr.
₹-0.75
(
